Jon C Aster

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3333148/publications.pdf

Version: 2024-02-01

216 papers	37,404 citations	2543 96 h-index	3102 187 g-index
221 all docs	221 docs citations	221 times ranked	38401 citing authors

#	Article	IF	Citations
1	Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clinical Cancer Research, 2023, 27, 852-864.	3.2	61
2	Notch signaling in cancer: Complexity and challenges on the path to clinical translation. Seminars in Cancer Biology, 2022, 85, 95-106.	4.3	17
3	A germinal centerâ€“associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL. Blood Advances, 2022, 6, 2388-2402.	2.5	8
4	Gamma Secretase Inhibition for a Child With Metastatic Glomus Tumor and Activated NOTCH1. JCO Precision Oncology, 2022, , .	1.5	3
5	Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood, 2021, 137, 2463-2480.	0.6	35
6	Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. Blood, 2021, 138, 2435-2440.	0.6	10
7	Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors. Blood Advances, 2021, 5, 71-83.	2.5	17
8	Activation of Notch and Myc Signaling via B-cellâ€“Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Research, 2021, 81, 6117-6130.	0.4	10
9	B Cell-Restricted Depletion of Dnmt3a Activates Notch Signaling and Causes Chronic Lymphocytic Leukemia. Blood, 2021, 138, 249-249.	0.6	0
10	A Distinctive Genomic and Immunohistochemical Profile for NOTCH3 and PDGFRB in Myofibroma With Diagnostic and Therapeutic Implications. International Journal of Surgical Pathology, 2020, 28, 128-137.	0.4	8
11	Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. Modern Pathology, 2020, 33, 1135-1145.	2.9	12
12	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. Blood, 2020, 136, 3051-3055.	0.6	15
13	suz12 inactivation in p53 and nf1 deficient zebrafish accelerates the onset of MPNSTs and expands the spectrum of tumor types to include adenocarcinoma, leukemia, and soft tissue sarcoma. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	9
14	A Novel SEC22B-NOTCH2 Fusion in Chronic Lymphocytic Leukemia. Human Pathology: Case Reports, 2020, 21, 200408.	0.2	1
15	Pharmacological disruption of the Notch transcription factor complex. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16292-16301.	3.3	64
16	Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 2025-2037.	3.3	27
17	MAML1-Dependent Notch-Responsive Genes Exhibit Differing Cofactor Requirements for Transcriptional Activation. Molecular and Cellular Biology, 2020, 40, .	1.1	5
18	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	13.5	334

#	Article	IF	Citations
19	IGH rearrangement in myeloid neoplasms. Haematologica, 2020, 105, e315-e317.	1.7	4
20	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Advances, 2020, 4, 925-929.	2.5	8
21	IER5, a DNA damage response gene, is required for Notch-mediated induction of squamous cell differentiation. ELife, 2020, 9, .	2.8	13
22	NOTCH SIGNALING IN CONTEXT: BASIC AND TRANSLATIONAL IMPLICATIONS. Transactions of the American Clinical and Climatological Association, 2020, 131, 147-156.	0.9	0
23	Targeted inhibition of CD47-SIRPÎ± requires Fc-FcÎ³R interactions to maximize activity in T-cell lymphomas. Blood, 2019, 134, 1430-1440.	0.6	45
24	Extension of the Notch intracellular domain ankyrin repeat stack by NRARP promotes feedback inhibition of Notch signaling. Science Signaling, 2019, 12, .	1.6	19
25	Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nature Protocols, 2019, 14, 2900-2930.	5.5	92
26	Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. PLoS ONE, 2019, 14, e0216810.	1.1	20
27	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. Cancer Discovery, 2019, 9, 944-961.	7.7	36
28	Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies. PLoS Genetics, 2019, 15, e1008039.	1.5	37
29	Oncogenic Notch Promotes Long-Range Regulatory Interactions within Hyperconnected 3D Cliques. Molecular Cell, 2019, 73, 1174-1190.e12.	4.5	83
30	Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell, 2019, 176, 1265-1281.e24.	13.5	642
31	Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation Via the Interplay of OATP2B1 and Dll4-Notch Signaling. Circulation, 2019, 139, 78-96.	1.6	126
32	Concomitant classic Hodgkin lymphoma and schistosomiasis. American Journal of Hematology, 2019, 94, 840-841.	2.0	1
33	DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. Journal of Clinical Investigation, 2019, 129, 5005-5019.	3.9	59
34	Single Cell RNA-Seq Reveals Deranged Developmental Hierarchy with Coexisting Oncogenic States and Immune Evasion Programs in ETP T-ALL. Blood, 2019, 134, 3953-3953.	0.6	0
35	Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL. Blood, 2019, 134, 3948-3948.	0.6	0
36	Activity of the PI3K-Î´,Î³ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood, 2018, 131, 888-898.	0.6	224

#	Article	IF	Citations
37	Metastatic penile carcinoma associated with convergent gain-of-function mutations in NOTCH1. Human Pathology: Case Reports, 2018, 11, 19-20.	0.2	1
38	RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood, 2018, 132, 935-947.	0.6	87
39	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nature Communications, 2018, 9, 2024.	5.8	80
40	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood, 2018, 132, 1495-1506.	0.6	100
41	Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and Tâ€ALL like mutations. American Journal of Hematology, 2018, 93, 1358-1367.	2.0	39
42	Single-Cell RNA-Seq Reveals AML Cellular Hierarchies Relevant to Clinical Outcomes and Immunity. Blood, 2018, 132, 542-542.	0.6	0
43	Detection of activatingMAP2K1mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leukemia and Lymphoma, 2017, 58, 233-236.	0.6	39
44	Genome-wide identification and characterization of Notch transcription complexâ€“binding sequence-paired sites in leukemia cells. Science Signaling, 2017, 10, .	1.6	39
45	The Varied Roles of Notch in Cancer. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 245-275.	9.6	511
46	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discovery, 2017, 7, 156-164.	7.7	164
47	Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell, 2017, 20, 233-246.e7.	5.2	387
48	Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell, 2017, 21, 547-555.e8.	5.2	71
49	A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Reports, 2017, 21, 784-797.	2.9	65
50	Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma. American Journal of Surgical Pathology, 2017, 41, 1473-1482.	2.1	32
51	An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017, 547, 217-221.	13.7	2,112
52	Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Advances, 2017, 1, 1786-1789.	2.5	13
53	The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia. PLoS ONE, 2017, 12, e0185762.	1.1	32
54	High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia. Blood, 2016, 128, 2229-2240.	0.6	33

#	Article	IF	Citations
55	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	7.7	227
56	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood, 2016, 127, 2203-2213.	0.6	68
57	Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell, 2016, 30, 750-763.	7.7	173
58	Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. Journal of Molecular Diagnostics, 2016, 18, 507-515.	1.2	144
59	An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nature Genetics, 2016, 48, 265-272.	9.4	216
60	Two-Year Experience of Performing a Next-Generation-Sequencing Based Panel Test in an Academic Medical Center and Its Clinical Impact. Blood, 2016, 128, 1707-1707.	0.6	3
61	T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development. Blood, 2016, 128, 3015-3015.	0.6	1
62	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax. Blood, 2016, 128, 4045-4045.	0.6	1
63	Notch-Regulated Enhancers in B-Cell Lymphoma Activate MYC and Potentiate B-Cell Receptor Signaling. Blood, 2016, 128, 457-457.	0.6	2
64	Generation of Models of Human Hematologic Malignancies Using CRISPR Genome Engineering. Blood, 2016, 128, 741-741.	0.6	3
65	Systematic STAT3 Mutation Testing Identifies Patients with Unsuspected T-Cell Large Granular Lymphocytic Leukemia. Blood, 2016, 128, 919-919.	0.6	0
66	Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression. Blood, 2016, 128, 753-753.	0.6	7
67	Therapeutic Targeting of PIM Protein Kinases in a Subset of T-Cell Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2742-2742.	0.6	0
68	Dicing up T-ALL. Blood, 2015, 126, 929-930.	0.6	5
69	A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors. Scientific Reports, 2015, 5, 11012.	1.6	29
70	Mechanical Allostery: Evidence for a Force Requirement in the Proteolytic Activation of Notch. Developmental Cell, 2015, 33, 729-736.	3.1	288
71	Insights into Autoregulation of Notch3 from Structural and Functional Studies of Its Negative Regulatory Region. Structure, 2015, 23, 1227-1235.	1.6	54
72	Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay. Journal of Physical Education and Sports Management, 2015, 1, a000307.	0.5	13

#	Article	IF	Citations
73	Ibrutinib in Previously Treated WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2015, 372, 1430-1440.	13.9	810
74	Network analysis of gene essentiality in functional genomics experiments. Genome Biology, 2015, 16, 239.	3.8	50
75	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the Î³-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Journal of Physical Education and Sports Management, 2015, 1, a000539.	0.5	47
76	Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2343-2353.	1.1	43
77	The Role of Notch Receptors in Transcriptional Regulation. Journal of Cellular Physiology, 2015, 230, 982-988.	2.0	107
78	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. Blood, 2015, 126, 3252-3252.	0.6	2
79	Modular Domains within a Super Enhancer Determine Drug Resistance in Leukemia. Blood, 2015, 126, 44-44.	0.6	3
80	Angiopoietin-like proteins stimulate HSPC development through interaction with notch receptor signaling. ELife, 2015, 4, .	2.8	30
81	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. Blood, 2015, 126, 4001-4001.	0.6	0
82	Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy. Blood, 2015, 126, 817-817.	0.6	5
83	NOTCH1â€“RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 705-710.	3.3	218
84	NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis. Journal of Investigative Dermatology, 2014, 134, 2630-2638.	0.3	287
85	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature Genetics, 2014, 46, 364-370.	9.4	333
86	Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4946-53.	3.3	151
87	Cyclin C is a haploinsufficient tumour suppressor. Nature Cell Biology, 2014, 16, 1080-1091.	4.6	124
88	Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature, 2014, 513, 512-516.	13.7	60
89	Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma. Cancer Discovery, 2014, 4, 1154-1167.	7.7	123
90	SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 226-242.	7.7	126

#	Article	IF	Citations
91	In Brief: Notch signalling in health and disease. Journal of Pathology, 2014, 232, 1-3.	2.1	47
92	Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nature Biotechnology, 2014, 32, 941-946.	9.4	477
93	MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene, 2014, 33, 1736-1742.	2.6	155
94	Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. Journal of Clinical Investigation, 2014, 124, 644-655.	3.9	180
95	Abstract IA8: A new class of drugs active in T-ALL is revealed in a zebrafish screen. , 2014, , .		0
96	Selectively Targeting Mutated NOTCH1 with a Folate-Thapsigargin Derivative. Blood, 2014, 124, 2158-2158.	0.6	1
97	Alternative Super-Enhancer States Determine MYC Sensitivity to Notch and Brd4 Inhibitors in T Lymphoblastic Leukemia/Lymphoma. Blood, 2014, 124, 863-863.	0.6	0
98	Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer. Cancer Cell, 2013, 23, 390-405.	7.7	130
99	Intrinsic Selectivity of Notch 1 for Delta-like 4 Over Delta-like 1. Journal of Biological Chemistry, 2013, 288, 25477-25489.	1.6	110
100	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS ONE, 2013, 8, e67306.	1.1	98
101	Angiopoietin-Like Proteins Stimulate HSC Development Through Direct Interaction With Notch. Blood, 2013, 122, 463-463.	0.6	0
102	RUNX1 Is Required For Maintenance Of Established T-ALL Blasts. Blood, 2013, 122, 3742-3742.	0.6	0
103	Preclinical Testing Of a PI3K Inhibitor In T Lineage Leukemia: Target Validation and Notch1/Myc Down-Regulation In Drug Resistant Clones. Blood, 2013, 122, 2677-2677.	0.6	0
104	Cutaneous Î²-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1473-80.	3.3	119
105	Targeting the Notch Pathway: Twists and Turns on the Road to Rational Therapeutics. Journal of Clinical Oncology, 2012, 30, 2418-2420.	0.8	59
106	Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2939-48.	3.3	292
107	The double-edged sword of Notch signaling in cancer. Seminars in Cell and Developmental Biology, 2012, 23, 458-464.	2.3	137
108	Collaboration Between RUNX and NOTCH Pathways in T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1279-1279.	0.6	2

#	Article	IF	Citations
109	Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor. Blood, 2012, 120, 3558-3558.	0.6	2
110	Genome-Wide Analysis of NOTCH1, ETS Family Factors, and RUNX1 Binding in Human T Lymphoblastic Leukemia Cells Reveals Distinct Regulatory Elements. Blood, 2012, 120, 1277-1277.	0.6	0
111	Defined, Serum-Free Conditions for in Vitro culture of Primary Human T-ALL Blasts. Blood, 2012, 120, 3537-3537.	0.6	0
112	Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14902-14907.	3.3	180
113	SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature, 2011, 471, 104-109.	13.7	558
114	Temporal Dissection of Tumorigenesis in Primary Cancers. Cancer Discovery, 2011, 1, 137-143.	7.7	240
115	Notch signalling in Tâ€cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. Journal of Pathology, 2011, 223, 263-274.	2.1	149
116	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17761-17766.	3.3	405
117	Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14908-14913.	3.3	221
118	T-cell factor 1 is a gatekeeper for T-cell specification in response to Notch signaling. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20060-20065.	3.3	182
119	Notch Ankyrin Repeat Domain Variation Influences Leukemogenesis and Myc Transactivation. PLoS ONE, 2011, 6, e25645.	1.1	9
120	Genome-Wide Analysis Reveals Conserved and Divergent Features of Notch1/RBPJ Binding in Human and Murine T Lymphoblastic Leukemia Cells. Blood, 2011, 118, 5236-5236.	0.6	0
121	Intersecting High-Throughput Screens Identifies SERCA As a Target for Modulating NOTCH1 In Hematopoietic Malignancies. Blood, 2011, 118, 555-555.	0.6	0
122	Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood, 2010, 116, 5443-5454.	0.6	68
123	Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood, 2010, 116, 5455-5464.	0.6	86
124	An asymptomatic 61â€yearâ€old man with BCRâ€ABLâ€positive bone marrow following autologous transplantation for multiple myeloma. American Journal of Hematology, 2010, 85, 944-946.	2.0	8
125	Structural and mechanistic insights into cooperative assembly of dimeric Notch transcription complexes. Nature Structural and Molecular Biology, 2010, 17, 1312-1317.	3.6	110
126	Characterization of Notch1 Antibodies That Inhibit Signaling of Both Normal and Mutated Notch1 Receptors. PLoS ONE, 2010, 5, e9094.	1.1	154

#	Article	IF	Citations
127	Notch dimerization is required for leukemogenesis and T-cell development. Genes and Development, 2010, 24, 2395-2407.	2.7	76
128	Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 252-257.	3.3	314
129	Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5012-5017.	3.3	149
130	High-Level Expression of Mastermind-Like 2 (MAML2) Contributes to Aberrant Activation of the NOTCH Signaling Pathway In Human Lymphomas. Blood, 2010, 116, 2685-2685.	0.6	0
131	Critical Functions for Notch Dimerization In T Cell Transformation.. Blood, 2010, 116, 3647-3647.	0.6	0
132	Deletion-Based Mechanisms of Notch1 Activation In T-ALL: Key Roles for RAG Recombinase and A Conserved Internal Translational Start Site In Notch1.. Blood, 2010, 116, 3367-3367.	0.6	5
133	Effects of S1 Cleavage on the Structure, Surface Export, and Signaling Activity of Human Notch1 and Notch2. PLoS ONE, 2009, 4, e6613.	1.1	90
134	Complexity Made Simple in Diffuse Large B-Cell Lymphoma. Clinical Cancer Research, 2009, 15, 5291-5293.	3.2	6
135	Direct inhibition of the NOTCH transcription factor complex. Nature, 2009, 462, 182-188.	13.7	712
136	Diagnosis of NUT Midline Carcinoma Using a NUT-specific Monoclonal Antibody. American Journal of Surgical Pathology, 2009, 33, 984-991.	2.1	364
137	Notch targeting 2.0. Blood, 2009, 113, 6044-6045.	0.6	3
138	Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood, 2009, 113, 1689-1698.	0.6	173
139	Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood, 2009, 113, 4381-4390.	0.6	154
140	Aggressive Langerhans cell histiocytosis following Tâ€ALL: Clonally related neoplasms with persistent expression of constitutively active NOTCH1. American Journal of Hematology, 2008, 83, 116-121.	2.0	63
141	Notch Signaling in Leukemia. Annual Review of Pathology: Mechanisms of Disease, 2008, 3, 587-613.	9.6	237
142	Mutational and Energetic Studies of Notch1 Transcription Complexes. Journal of Molecular Biology, 2008, 376, 131-140.	2.0	54
143	Canonical Notch Signaling Is Dispensable for theÂMaintenance of Adult Hematopoietic Stem Cells. Cell Stem Cell, 2008, 2, 356-366.	5.2	271
144	Notch Signaling Specifies Megakaryocyte Development from Hematopoietic Stem Cells. Cell Stem Cell, 2008, 3, 314-326.	5.2	117

#	Article	IF	Citations
145	Modulation of Notch Signaling by Antibodies Specific for the Extracellular Negative Regulatory Region of NOTCH3. Journal of Biological Chemistry, 2008, 283, 8046-8054.	1.6	177
146	NUT Rearrangement in Undifferentiated Carcinomas of the Upper Aerodigestive Tract. American Journal of Surgical Pathology, 2008, 32, 828-834.	2.1	201
147	Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-rasâ€“initiated leukemia. Journal of Clinical Investigation, 2008, 118, 3181-3194.	3.9	194
148	Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL. Blood, 2008, 112, 200-200.	0.6	0
149	Delta-Like 4 Induces Notch Signaling in Macrophages. Circulation, 2007, 115, 2948-2956.	1.6	196
150	Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2007, 25, 1741-1746.	0.8	235
151	Cooperative assembly of higher-order Notch complexes functions as a switch to induce transcription. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2103-2108.	3.3	145
152	Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood, 2007, 110, 278-286.	0.6	263
153	The multifaceted role of Notch in cancer. Current Opinion in Genetics and Development, 2007, 17, 52-59.	1.5	271
154	Structural basis for autoinhibition of Notch. Nature Structural and Molecular Biology, 2007, 14, 295-300.	3.6	317
155	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature, 2007, 447, 966-971.	13.7	355
156	Notch Signaling Induces Megakaryocytic Cell Fate.. Blood, 2007, 110, 200-200.	0.6	0
157	c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes and Development, 2006, 20, 2096-2109.	2.7	782
158	Structural Basis for Cooperativity in Recruitment of MAML Coactivators to Notch Transcription Complexes. Cell, 2006, 124, 973-983.	13.5	390
159	Activating Notch1 mutations in mouse models of T-ALL. Blood, 2006, 107, 781-785.	0.6	215
160	Tribbles homolog 2 inactivates C/EBPÎ± and causes acute myelogenous leukemia. Cancer Cell, 2006, 10, 401-411.	7.7	232
161	Leukemia-Associated Mutations within the NOTCH1 Heterodimerization Domain Fall into at Least Two Distinct Mechanistic Classes. Molecular and Cellular Biology, 2006, 26, 4642-4651.	1.1	241
162	Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. Journal of Experimental Medicine, 2006, 203, 311-317.	4.2	326

#	Article	IF	Citations
163	Identification of a Conserved Negative Regulatory Sequence That Influences the Leukemogenic Activity of NOTCH1. Molecular and Cellular Biology, 2006, 26, 6261-6271.	1.1	86
164	NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18261-18266.	3.3	745
165	Hodgkinâ€™s Lymphoma Reed Sternberg Cells over Express the T-Cell Inhibitory Carbohydrate-Binding Lectin, Galectin 1: Role of AP-1 and Likely Mechanism of Tumor Immune Escape.. Blood, 2006, 108, 469-469.	0.6	1
166	Sporadic Notch1 Mutations Found in Human T-ALL Drive T Cell Development but Not Leukemogenesis in Murine Models: Implications for Pathogenesis and gamma-Secretase Inhibitor (GSI) Therapy.. Blood, 2006, 108, 707-707.	0.6	1
167	Tribbles Homolog 2 (Trib2) Inactivates C/EBPalpha and Causes Acute Myelogenous Leukemia.. Blood, 2006, 108, 776-776.	0.6	4
168	NOTCH1-Induced T-Cell Leukemia in Transgenic Zebrafish.. Blood, 2006, 108, 1825-1825.	0.6	0
169	Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood, 2005, 106, 3898-3906.	0.6	186
170	Deregulated NOTCH Signaling in Acute T-Cell Lymphoblastic Leukemia/Lymphoma: New Insights, Questions, and Opportunities. International Journal of Hematology, 2005, 82, 295-301.	0.7	37
171	Notch signaling controls the generation and differentiation of early T lineage progenitors. Nature Immunology, 2005, 6, 663-670.	7.0	320
172	BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma. Current Biology, 2005, 15, 249-254.	1.8	626
173	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood, 2005, 105, 1851-1861.	0.6	778
174	Activating Notch1 Mutations in Mouse Models of T-ALL.. Blood, 2005, 106, 2609-2609.	0.6	2
175	Canonical Notch Signaling Is Dispensable for the Maintenance of Adult Hematopoietic Stem Cells.. Blood, 2005, 106, 267-267.	0.6	42
176	Transcriptional Regulatory Networks Downstream of NOTCH1 in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 740-740.	0.6	15
177	A New Recurrent 9q34 Duplication in Pediatric T-Cell Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 89-89.	0.6	1
178	Identification of a C-Terminal Negative Regulatory Sequence in NOTCH1 That Influences Signal Strength and Leukemogenic Activity.. Blood, 2005, 106, 535-535.	0.6	0
179	Functional Analysis of Leukemia-Associated Mutations Involving the Heterodimerization Domain of NOTCH1.. Blood, 2005, 106, 843-843.	0.6	1
180	Notch Subunit Heterodimerization and Prevention of Ligand-Independent Proteolytic Activation Depend, Respectively, on a Novel Domain and the LNR Repeats. Molecular and Cellular Biology, 2004, 24, 9265-9273.	1.1	186

#	Article	IF	Citations
181	JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence. Cancer Research, 2004, 64, 6854-6857.	0.4	310
182	Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia. Science, 2004, 306, 269-271.	6.0	2,494
183	Multiple niches for Notch in cancer: context is everything. Current Opinion in Genetics and Development, 2004, 14, 48-54.	1.5	198
184	Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood, 2004, 104, 1696-1702.	0.6	265
185	Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.. Blood, 2004, 104, 25-25.	0.6	1
186	Gain-of-Function NOTCH1 Mutations Occur Frequently in Human T Cell Acute Lymphoblastic Leukemia.. Blood, 2004, 104, 4-4.	0.6	4
187	NFÎºB Activation in Primary Mediastinal Large B-Cell Lymphoma: Nuclear Localization of c-REL and Coordinate Upregulation of NFÎºB Target Genes.. Blood, 2004, 104, 243-243.	0.6	11
188	Efficient Inhibition of Notch3 and Notch4 Family Members In Vivo by a Dominant Negative Mutant of Mastermind.. Blood, 2004, 104, 1617-1617.	0.6	0
189	Intrathymic and Extrathymic Notch-Dependent T Lineage Checkpoints during Normal Development and after Bone Marrow Transplantation.. Blood, 2004, 104, 1190-1190.	0.6	0
190	F3/Contactin Acts as a Functional Ligand for Notch during Oligodendrocyte Maturation. Cell, 2003, 115, 163-175.	13.5	332
191	Growth Suppression of Pre-T Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling. Molecular and Cellular Biology, 2003, 23, 655-664.	1.1	341
192	Structural Requirements for Assembly of the CSLÂ·Intracellular Notch1Â·Mastermind-like 1 Transcriptional Activation Complex. Journal of Biological Chemistry, 2003, 278, 21232-21239.	1.6	178
193	Myc-Induced T Cell Leukemia in Transgenic Zebrafish. Science, 2003, 299, 887-890.	6.0	506
194	The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood, 2003, 102, 3871-3879.	0.6	793
195	Notch Signaling in Cancer. Cancer Biology and Therapy, 2002, 1, 466-476.	1.5	311
196	Detection of BCL2 Rearrangements in Follicular Lymphoma. American Journal of Pathology, 2002, 160, 759-763.	1.9	76
197	Deltex1 Redirects Lymphoid Progenitors to the B Cell Lineage by Antagonizing Notch1. Immunity, 2002, 16, 231-243.	6.6	235
198	Notch signaling as a therapeutic target. Current Opinion in Chemical Biology, 2002, 6, 501-509.	2.8	63

#	Article	IF	Citations
199	Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine, 2002, 8, 68-74.	15.2	2,217
200	Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nature Medicine, 2002, 8, 979-986.	15.2	506
201	BRD4 Bromodomain Gene Rearrangement in Aggressive Carcinoma with Translocation t(15;19). American Journal of Pathology, 2001, 159, 1987-1992.	1.9	188
202	Notch signaling in leukemia. Current Opinion in Hematology, 2001, 8, 237-244.	1.2	62
203	Separation of Notch1 Promoted Lineage Commitment and Expansion/Transformation in Developing T Cells. Journal of Experimental Medicine, 2001, 194, 99-106.	4.2	165
204	MAML1, a human homologue of Drosophila Mastermind, is a transcriptional co-activator for NOTCH receptors. Nature Genetics, 2000, 26, 484-489.	9.4	506
205	Molecular Biology of Burkittâ€™s Lymphoma. Journal of Clinical Oncology, 2000, 18, 3707-3721.	0.8	386
206	Calcium Depletion Dissociates and Activates Heterodimeric Notch Receptors. Molecular and Cellular Biology, 2000, 20, 1825-1835.	1.1	368
207	Essential Roles for Ankyrin Repeat and Transactivation Domains in Induction of T-Cell Leukemia by Notch1. Molecular and Cellular Biology, 2000, 20, 7505-7515.	1.1	255
208	Stat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2. Molecular Cell, 2000, 6, 693-704.	4.5	289
209	Rapid Notch1 Nuclear Translocation after Ligand Binding Depends on Presenilinâ€associated Î³â€Secretase Activity. Annals of the New York Academy of Sciences, 2000, 920, 223-226.	1.8	29
210	Lymphocyte-Predominant Hodgkin's Disease: How Little Therapy Is Enough?. Journal of Clinical Oncology, 1999, 17, 744-744.	0.8	5
211	Notch1 Expression in Early Lymphopoiesis Influences B versus T Lineage Determination. Immunity, 1999, 11, 299-308.	6.6	853
212	Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO Journal, 1998, 17, 5321-5333.	3.5	249
213	FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nature Genetics, 1998, 18, 84-87.	9.4	301
214	Primary-Effusion Lymphoma and Kaposi's Sarcoma in a Cardiac-Transplant Recipient. New England Journal of Medicine, 1998, 339, 444-449.	13.9	169
215	Oncogenic Forms of NOTCH1 Lacking Either the Primary Binding Site for RBP-JÎº or Nuclear Localization Sequences Retain the Ability to Associate with RBP-JÎº and Activate Transcription. Journal of Biological Chemistry, 1997, 272, 11336-11343.	1.6	164
216	Inhibition of DNA replication factor RPA by p53. Nature, 1993, 365, 79-82.	13.7	373